Clinical Trial Update: Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of lenvatinib, tislelizumab, gemcitabine, and cisplatin (GPLET) for advanced cholangiocarcinoma; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• LENVIMA (lenvatinib)
• Platinol (cisplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Advanced Cholangiocarcinoma | Phase 2 | Status: RECRUITING